This is a phase Ia/Ib study to evaluate the toxicity and immunologic response following administration of the recombinant vaccinia-CEA vaccine to patients with resected colorectal cancer who have no evidence of disease but are at high risk for disease recurrence.
Showing the most recent 10 out of 570 publications